中信证券保荐维立志博完成今年以来超额认购倍数最高的港股18A IPO

中信证券发布
25 Jul

2025年7月25日,南京维立志博生物科技股份有限公司(以下简称维立志博,9887.HK)成功在香港联交所主板上市,基础发行规模1.43亿美元,发售量调整权和超额配售权均悉数行使后,最高发行规模1.89亿美元,中信证券担任联席保荐人、联席整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。项目亮点提前助力引入多家顶级基石投资者簿记建档环节吸引多元化优质投资者踊跃下单,实现发行区间上限定价...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10